Invivyd

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.

Invivyd strives to improve healthcare delivery by creating a platform that allows patients to access the best possible care with reduced wait times and increased satisfaction.

Invivyd's vision is to unlock the potential of digital healthcare to create a better healthcare experience for all.

Invivyd has been recognized by the World Economic Forum, Forbes, and KPMG for their innovative solutions. They have also won multiple awards from the European Commission, including the European Social Impact Award and the Digital Health Innovation Award. Invivyd was also a winner of the EU HealthTech Challenge 2020.